{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:30:42Z","timestamp":1790501442555,"version":"4.1.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.thromres.2019.07.010","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T11:12:38Z","timestamp":1563275558000},"page":"579-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["How we make an accurate diagnosis of von Willebrand disease"],"prefix":"10.1016","volume":"196","author":[{"given":"Luciano","family":"Baronciani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2019.07.010_bb0005","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1111\/jth.12008","article-title":"von Willebrand factor: the old, the new and the unknown","volume":"10","author":"Lenting","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0010","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1046\/j.1538-7836.2003.00260.x","article-title":"Von Willebrand factor, platelets and endothelial cell interactions","volume":"1","author":"Ruggeri","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0015","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1172\/JCI108788","article-title":"Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand\u2019s disease","volume":"60","author":"Weiss","year":"1977","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2019.07.010_bb0020","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1021\/bi00359a014","article-title":"cDNA sequences for human von Willebrand factor reveal five types of repeated domains and five possible protein sequence polymorphisms","volume":"25","author":"Shelton-Inloes","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2019.07.010_bb0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2012-01-405134","article-title":"Sequence and structure relationships within von Willebrand factor","volume":"120","author":"Zhou","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0030","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2014-05-378638","article-title":"von Willebrand factor, Jedi knight of the bloodstream","volume":"124","author":"Springer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0035","doi-asserted-by":"crossref","first-page":"13497","DOI":"10.1016\/S0021-9258(18)80024-2","article-title":"In vitro multimerization of von Willebrand factor is triggered by low pH: importance of the propolypeptide and free sulfhydryls","volume":"264","author":"Mayadas","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2019.07.010_bb0040","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0045","first-page":"S41","article-title":"Perspective series: cell adhesion in vascular biology. von Willebrand Factor","volume":"100","author":"Ruggeri","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2019.07.010_bb0050","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/S0021-9258(18)47430-3","article-title":"A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor","volume":"262","author":"Foster","year":"1987","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2019.07.010_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0065","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0037-1613992","article-title":"Impact, diagnosis and treatment of von Willebrand Disease","volume":"84","author":"Sadler","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0075","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","article-title":"Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor","volume":"4","author":"Sadler","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0080","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.13204","article-title":"Platelet type von Willebrand disease and registry report: communication from the SSC of the ISTH","volume":"14","author":"Othman","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0085","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.transci.2018.10.012","article-title":"Management of acquired von Willebrand syndrome","volume":"57","author":"Charlebois","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"10.1016\/j.thromres.2019.07.010_bb0090","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1334867","article-title":"Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update","volume":"39","author":"Federici","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0095","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1538-7836.2005.01663.x","article-title":"The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study","volume":"3","author":"Rodeghiero","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0100","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1538-7836.2006.01847.x","article-title":"A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)","volume":"4","author":"Tosetto","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/asheducation.V2012.1.152.3798226","article-title":"Bleeding scores: are they really useful?","volume":"2012","author":"O\u2019Brien","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.thromres.2019.07.010_bb0110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jth.13883","article-title":"The ISTH bleeding assessment tool and the risk of future bleeding","volume":"16","author":"Fasulo","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1538-7836.2011.04265.x","article-title":"Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation","volume":"9","author":"Tosetto","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0120","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1182\/blood-2007-08-105940","article-title":"Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach","volume":"111","author":"Tosetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0125","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1538-7836.2005.01245.x","article-title":"Provisional criteria for the diagnosis of VWD type 1","volume":"3","author":"Sadler","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1182\/blood-2008-04-152280","article-title":"Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients","volume":"113","author":"Federici","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0135","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00043426-200306000-00009","article-title":"Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems","volume":"25","author":"Cariappa","year":"2003","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2019.07.010_bb0140","first-page":"106","article-title":"Description of an in vitro platelet function analyzer\u2014PFA-100","volume":"21","author":"Kundu","year":"1995","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0049-3848(99)00102-4","article-title":"Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion","volume":"96","author":"Cattaneo","year":"1999","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.07.010_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0037-1614626","article-title":"Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease","volume":"82","author":"Cattaneo","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0155","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2010.08333.x","article-title":"The impact of bleeding history, von Willebrand factor and PFA-100((R)) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD","volume":"151","author":"Castaman","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0160","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease","volume":"69","author":"Gill","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0165","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","article-title":"von Willebrand disease and aging: an evolving phenotype","volume":"12","author":"Sanders","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0170","doi-asserted-by":"crossref","unstructured":"Eikenboom J, Van M, V, Putter H, Goodeve A, Rodeghiero F, Castaman G, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J. Thromb. Haemost. 2006; 4: 774\u201382.","DOI":"10.1111\/j.1538-7836.2006.01823.x"},{"key":"10.1016\/j.thromres.2019.07.010_bb0175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1538-7836.2006.01860.x","article-title":"Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study","volume":"4","author":"James","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0180","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood-2002-09-2892","article-title":"Von Willebrand disease type 1: a diagnosis in search of a disease","volume":"101","author":"Sadler","year":"2003","journal-title":"Blood"},{"issue":"Suppl. 77","key":"10.1016\/j.thromres.2019.07.010_bb0185","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ejh.12500","article-title":"One-stage vs. chromogenic assays in haemophilia A","volume":"94","author":"Potgieter","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0190","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/clinchem\/28.6.1356","article-title":"Enzyme immunoassay for factor VIII-related antigen","volume":"28","author":"Cejka","year":"1982","journal-title":"Clin. Chem."},{"key":"10.1016\/j.thromres.2019.07.010_bb0195","first-page":"77","article-title":"A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ib\u03b1 for the diagnosis of patients with low von Willebrand factor levels","volume":"89","author":"Federici","year":"2004","journal-title":"Haematol"},{"key":"10.1016\/j.thromres.2019.07.010_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/s-0037-1614468","article-title":"A new automated method for von Willebrand factor antigen measurement using latex particles","volume":"81","author":"Veyradier","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0205","article-title":"Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease","volume":"10","author":"Verfaillie","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0210","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1172\/JCI107465","article-title":"Quantitative assay of a plasma factor deficient in von Willebrand\u2019s disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content","volume":"52","author":"Weiss","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2019.07.010_bb0215","first-page":"306","article-title":"A method for assaying von Willebrand factor (ristocetin cofactor)","volume":"34","author":"MacFarlane","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.thromres.2019.07.010_bb0220","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/j.1538-7836.2010.04029.x","article-title":"Improved performance characteristics of the von Willebrand factor ristocetin cofactor activity assay using a novel automated assay protocol","volume":"8","author":"Hillarp","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 4","key":"10.1016\/j.thromres.2019.07.010_bb0225","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2516.2012.02830.x","article-title":"Difficulties and pitfalls in the laboratory diagnosis of bleeding disorders","volume":"18","author":"Bolton-Maggs","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0230","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/jth.12964","article-title":"Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH","volume":"13","author":"Bodo","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0235","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3324\/haematol.10766","article-title":"Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease","volume":"92","author":"Pinol","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2019.07.010_bb0240","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1076029606291428","article-title":"Determination of von Willebrand factor activity: evaluation of the HaemosIL assay in comparison with established procedures","volume":"12","author":"Sucker","year":"2006","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0245","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/hae.12203","article-title":"Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method","volume":"19","author":"Cabrera","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/hae.12264","article-title":"A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen","volume":"20","author":"Stufano","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0255","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH14-02-0108","article-title":"Performance of two new automated assays for measuring von Willebrand activity: HemosIL AcuStar and Innovance","volume":"112","author":"de Maistre","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0260","article-title":"An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study","volume":"10","author":"Szederjesi","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12064","article-title":"A comparative evaluation of a new automated assay for von Willebrand factor activity","volume":"19","author":"Lawrie","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0270","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/MBC.0000000000000169","article-title":"Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin","volume":"25","author":"Patzke","year":"2014","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2019.07.010_bb0275","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.thromres.2014.04.033","article-title":"Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo","volume":"134","author":"Geisen","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.07.010_bb0280","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.12218","article-title":"Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin","volume":"36","author":"Graf","year":"2014","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0285","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12380","article-title":"Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies","volume":"20","author":"Costa-Pinto","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0290","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1111\/jth.14319","article-title":"Clinically relevant differences between assays for von Willebrand factor activity","volume":"16","author":"Boender","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0295","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.20470","article-title":"von Willebrand disease R1374C: type 2A or 2M? A challenge to the revised classification. High frequency in the northwest of Spain (Galicia)","volume":"80","author":"Penas","year":"2005","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0300","doi-asserted-by":"crossref","unstructured":"Michiels JJ, Berneman Z, Gadisseur A, Van der PM, Schroyens W, van d, V, van Vliet H. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin. Appl. Thromb. Hemost. 2006; 12: 397\u2013420.","DOI":"10.1177\/1076029606293422"},{"key":"10.1016\/j.thromres.2019.07.010_bb0305","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0037-1616142","article-title":"Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen","volume":"86","author":"Ribba","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0310","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood.V68.3.668.668","article-title":"von Willebrand\u2019s disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma","volume":"68","author":"Holmberg","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0315","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/blood.V68.1.149.149","article-title":"A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers","volume":"68","author":"Weiss","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0320","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2012-09-455089","article-title":"VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease","volume":"121","author":"Eikenboom","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0325","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1182\/blood.V57.6.1140.1140","article-title":"The complex multimeric composition of factor VIII\/von Willebrand factor","volume":"57","author":"Ruggeri","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0330","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease","volume":"71","author":"Sadler","year":"1994","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0335","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1172\/JCI112394","article-title":"Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID and IIE)","volume":"77","author":"Zimmerman","year":"1986","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2019.07.010_bb0340","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1073\/pnas.93.8.3581","article-title":"Difective dimerization of the von Willebrand factor subunits due to a Cys\u2192Arg mutation in type IID von Willebrand disease","volume":"93","author":"Schneppenheim","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.thromres.2019.07.010_bb0345","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/rth2.12141","article-title":"Evaluation of a semi-automated von Willebrand factor multimer assay, the Hydragel 5 von Willebrand multimer, by two European Centers","volume":"2","author":"Bowyer","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0350","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.thromres.2015.12.010","article-title":"Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease","volume":"141","author":"Favaloro","year":"2016","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.07.010_bb0355","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003038","article-title":"A Laboratory Phenotype\/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture","volume":"95","author":"Veyradier","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.thromres.2019.07.010_bb0360","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2014-11-610824","article-title":"Crucial role for the VWF A1 domain in binding to type IV collagen","volume":"125","author":"Flood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0365","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1538-7836.2012.04746.x","article-title":"Critical von Willebrand factor A1 domain residues influence type VI collagen binding","volume":"10","author":"Flood","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0370","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1111\/hae.13156","article-title":"VWF collagen (types III and VI)-binding defects in a cohort of type 2M VWD patients - a strategy for improvement of a challenging diagnosis","volume":"23","author":"Fidalgo","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0375","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/ajcp\/109.3.347","article-title":"The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications","volume":"109","author":"Casonato","year":"1998","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0380","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/jth.12280","article-title":"I, Solimando M, La Marca S, Cozzi G, Stufano F, Canciani MT, Peyvandi F. A synonymous (c.3390C>T) or a splice-site (c.3380-2A>G) mutation causes exon 26 skipping in four patients with von Willebrand disease (2A\/IIE)","volume":"11","author":"Pagliari","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0385","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0038-1655973","article-title":"Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) levels","volume":"77","author":"Vischer","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0390","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1182\/blood.V94.1.179.413k18_179_185","article-title":"von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation","volume":"94","author":"van Mourik","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0395","first-page":"10","article-title":"Evaluation of the utility of von Willebrand factor propeptide in the differential diagnosis of von Willebrand disease and acquired von Willebrand syndrome","author":"Stufano","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0400","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1182\/blood-2006-04-015065","article-title":"Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival","volume":"108","author":"Haberichter","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0405","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1055\/s-0037-1615235","article-title":"Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome","volume":"80","author":"van Genderen","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0410","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1182\/blood-2014-02-557132","article-title":"Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0415","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","article-title":"The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels","volume":"121","author":"Rydz","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0420","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/jth.12927","article-title":"CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease","volume":"13","author":"Sanders","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0425","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V99.1.180","article-title":"Reduced von Willebrand factor survival in type Vicenza von Willebrand disease","volume":"99","author":"Casonato","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2141.2008.07311.x","article-title":"Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease","volume":"143","author":"Sztukowska","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2019.07.010_bb0435","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/blood-2014-09-603241","article-title":"von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease","volume":"125","author":"Sanders","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0440","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJM198005083021902","article-title":"Heightened interaction between platelets and factor VIII\/von Willebrand factor in a new subtype of von Willebrand\u2019s disease","volume":"302","author":"Ruggeri","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.07.010_bb0445","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJM198202113060603","article-title":"Pseudo-von Willebrand\u2019s disease: an intrinsic platelet defect with aggregation by unmodified human factor VIII\/von Willebrand factor and enhanced adsorption of its high molecular weight multimers","volume":"306","author":"Weiss","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2019.07.010_bb0450","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1538-7836.2007.02349.x","article-title":"Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease","volume":"5","author":"Baronciani","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0455","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/hae.13175","article-title":"Molecular diagnosis of von Willebrand disease","volume":"23","author":"Baronciani","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0460","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0049-3848(90)90129-Z","article-title":"Platelet von Willebrand factor assay: results using two methods for platelet lysis","volume":"59","author":"Rodeghiero","year":"1990","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.07.010_bb0465","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V71.5.1366.1366","article-title":"Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin","volume":"71","author":"Moake","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0470","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V66.4.796.796","article-title":"Heterogeneity of Type I von Willebrand Disease: Evidence for a Subgroup with an Abnormal von Willebrand Factor","volume":"66","author":"Mannucci","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0475","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/bi00215a036","article-title":"Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction","volume":"30","author":"Mancuso","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.thromres.2019.07.010_bb0480","article-title":"Molecular and clinical profile of von Willebrand disease in Spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm","volume":"114","author":"Batlle","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2019.07.010_bb0485","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","article-title":"Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand disease (MCMDM-1VWD)","volume":"109","author":"Goodeve","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0490","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105","article-title":"The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study","volume":"109","author":"James","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0495","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/j.1365-2516.2009.02078.x","article-title":"Multiplex ligation-dependent probe amplification to detect a large deletion within the von Willebrand gene","volume":"15","author":"Acquila","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2019.07.010_bb0500","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2019.07.010_bb0505","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.thromres.2017.09.025","article-title":"Von Willebrand disease mutation spectrum and associated mutation mechanisms","volume":"159","author":"De Jong","year":"2017","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2019.07.010_bb0510","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1016\/S0021-9258(18)42852-9","article-title":"Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations","volume":"267","author":"Lyons","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2019.07.010_bb0515","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1055\/s-0037-1615051","article-title":"Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand\u2019s disease","volume":"79","author":"Holmberg","year":"1998","journal-title":"Thromb. Haemost."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819302932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384819302932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:47:51Z","timestamp":1758736071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384819302932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":103,"alternative-id":["S0049384819302932"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2019.07.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we make an accurate diagnosis of von Willebrand disease","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2019.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}